Enhanced Genomics is a biotechnology company that is making significant strides in the realm of drug development through its innovative use of 3D multi-omics technology. Recently, the company announced that it has completed a new financing round, bringing its total Series A funding to an impressive $19 million. This round of funding was made possible with the participation of several notable investors, including BGF, Parkwalk, and Meltwind.
The purpose of this newly raised capital is to enhance further Enhanced Genomics’ therapeutic pipeline, particularly targeting common diseases. Among the critical areas of focus are autoimmune conditions, such as inflammatory bowel disease, which affects a significant number of individuals worldwide. With this financial boost, Enhanced Genomics plans to expand its research and development efforts. This will involve creating new partnerships with pharmaceutical companies and biotechnology firms, which will be essential in leveraging their discoveries for maximum impact.
What sets Enhanced Genomics apart from other biotechnology companies is its unique ability to identify genetically validated drug targets for complex genetic diseases. In this area, there is a significant unmet medical need. The company utilizes a proprietary 3D multi-omics platform, along with a detailed cell-type-specific atlas. This technological advantage enables them to explore and define the causal biology underlying disease-associated genetic variants. By focusing on the most relevant cell types, Enhanced Genomics can gather valuable insights into the genetic basis of diseases, leading to more effective treatment options.
Through their work, Enhanced Genomics transforms vast amounts of disease-related data into actionable insights. This process enables them to identify high-confidence drug targets that are strongly supported by genetic evidence. As a result, their approach significantly increases the likelihood of success in developing new pharmaceuticals while also reducing the time and costs typically associated with such endeavors.
KEY QUOTE:
“Our founders have led the field by developing technology to map 3D interactions on a whole-genome scale, and integrating these data with comprehensive multi-omics datasets. We now have the technological capabilities to decipher the causal biology that drives complex and common genetic diseases, with the potential to develop truly effective new blockbuster therapies. This puts us in a strong position to lead the next major shift in pharma. When developing a novel approach to drug discovery, clarity of thought and courage are required to build deep conviction, and we are proud to have built a team that embodies this. We thank our investors for continuing to support our vision.”
Dietrich A. Stephan, Ph.D., Chair, Enhanced Genomics